The first Chinese patent for a COVID-19 vaccine granted through the country’s National Intellectual Property Administration.
Also on Monday, the South African University of Witwatersrand presented the COVID-19 vaccine trial in the country.
The Chinese patent filed jointly through a research team with the Academy of Military Sciences and CanSino Biologics Inc., a Chinese high-tech biopharmaceutical company, said a report at People’s Daily.
The team, led by Chen Wei, a researcher at the Academy’s Institute of Military Medicine, developed the recombinant COVID-19 vaccine, with defective adenovirus modified as a vector.
In March, the vaccine was the first vaccine in China to be approved for clinical trials.
According to the abbreviation of the patent, the vaccine has immunogenicity in mouse and guinea pig models and can induce a strong and fun cellular immune reaction in a short period of time.
It can be temporarily produced on a giant scale to cope with an outbreak of COVID-19.
However, Shabir Madhi, executive director of the Vaccine analysis and infectious diseases research unit at the South African Medical Research Council (VIDA) in Wits and dean-elect of the Faculty of Health Sciences, said he would lead the U.S. Phase II trial. NVX-CoV2373 vaccine produced, which is produced throughout the United States.
Like it on Facebook to see stories
Please give an overview of the site: